Pfizer announced on Monday that it will acquire Metsera, a biotechnology company developing weight-loss treatments, in a deal valued at up to $7.3 billion as it moves aggressively to establish a stronger presence in the fast-growing obesity drug market.
Under the terms of the agreement, Pfizer will pay $47.50 per share in cash, a 43% premium to Metsera’s last closing price. The deal also includes up to $22.50 per share in contingent payments tied to future performance milestones, bringing the total potential value to $7.3 billion. News of the acquisition sent Metsera’s shares surging 56% in premarket trading on Monday.
The move comes as the U.S. obesity treatment market experiences explosive growth, driven by demand for next-generation incretin-based drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Analysts estimate the sector could grow into a market worth tens of billions of dollars annually, though questions remain over affordability, insurance coverage, and long-term supply.
For Pfizer, the deal represents a strategic pivot after setbacks with its own weight-loss drug development. The company discontinued late-stage studies of danuglipron, its oral obesity treatment candidate, citing tolerability concerns that limited its potential. By acquiring Metsera, Pfizer gains access to a pipeline of obesity therapies at a time when competitors are racing ahead in what has become one of the most lucrative areas in the pharmaceutical industry.
“Obesity is a major health challenge, and this acquisition underscores our commitment to addressing it with innovative treatments,” Pfizer said in a statement.
The acquisition is part of a broader push by Pfizer to diversify its portfolio following declining revenues from its COVID-19 vaccine and antiviral treatments. Like many of its peers, the company is betting on obesity drugs to drive growth over the next decade.
Metsera, based in New York, has positioned itself as a rising contender in the obesity and metabolic disorder space. While details of its clinical programs remain limited, analysts note the company has promising early-stage assets that could complement Pfizer’s existing expertise in endocrinology and metabolic disease.
Industry observers say the deal highlights the intensifying competition in the obesity drug sector. Novo Nordisk and Eli Lilly have already secured strong footholds with products that have shown unprecedented weight-loss results, prompting other pharmaceutical companies to scramble for opportunities to catch up.
The Financial Times first reported on the acquisition on Sunday. Pfizer expects the deal to close in the coming months, subject to regulatory approvals and customary closing conditions.
If completed, the acquisition could reshape Pfizer’s long-term growth trajectory, giving it a vital stake in one of the most closely watched and profitable areas of modern medicine.
